<DOC>
	<DOCNO>NCT00957073</DOCNO>
	<brief_summary>The purpose HOPE4HF trial demonstrate safety efficacy Rheos Baroreflex Activation Therapy System subject heart failure EF ≥ 40 % prospective , randomized trial .</brief_summary>
	<brief_title>Rheos HOPE4HF ( Health Outcomes Prospective Evaluation Heart Failure With Ejection Fraction ( EF ) ≥ 40 % ) Trial</brief_title>
	<detailed_description>This study close enrollment adequate endpoint data collect enrollment complete . The study stop safety futility , business/strategic reason due production new generation device . Currently , subject still enrol trial long-term follow-up .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>At least 21 year age Have bilateral carotid bifurcation level mandible Have leave ventricular ejection fraction ≥ 40 % Symptomatic heart failure elevate blood pressure Elevated brain natriuretic peptide ( BNP ) nterminal probrain natriuretic peptide ( NTproBNP ) Serum creatine ≤ 2.5 mg/dL treat dialysis Known suspect baroreflex failure autonomic neuropathy History symptomatic bradyarrhythmias , pericardial constriction , infiltrative cardiomyopathy , primary hypertrophic cardiomyopathy Solid organ hematologic transplant History prior surgery , radiation , stent placement carotid sinus region Life expectancy less one year noncardiovascular reason</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Diastolic dysfunction</keyword>
</DOC>